Lindh M, Gustavson C, Mårdberg K, Norkrans G, Dhillon A P, Horal P
Department of Clinical Virology, Göteborg University, Sweden.
J Med Virol. 1998 Jul;55(3):185-90. doi: 10.1002/(sici)1096-9071(199807)55:3<185::aid-jmv1>3.0.co;2-y.
In chronic hepatitis B virus (HBV) infection, mutations develop frequently at nucleotides 1,762/1,764 in the X protein open reading frame, where the core promoter is also located. By using a modified allele-specific polymerase chain reaction method, the longitudinal emergence of the A-->T mutation at nucleotide 1,762 was studied in relation to precore mutations, genotype, and liver damage. First, samples from 38 carriers that were drawn before and after hepatitis B e (HBe) seroconversion were tested. T-1,762 mutant strains increased during HBe seroconversion (P = 0.004). In the HBe antigen-negative (HBeAg-) phase, T-1,762 mutants were found in 71% (12 of 17) of patients without compared with 33% (6 of 18) of patients with a concomitant precore mutation that prevents HBeAg synthesis (P = 0.08). Second, in 55 HBeAg+ patients, the T-1,762 mutant was found to be associated with more liver inflammation (P = 0.04) and fibrosis (P = 0.02), as measured by histology activity index (HAI) scores. The results show that the nucleotide (nt) 1,762 A-->T mutation often develops during HBe seroconversion, particularly in strains without precore mutations that prevent HBeAg production. For unknown reasons, the T-1,762 mutant was rare in genotype B strains. The presence of a T-1,762 mutant in the HBeAg+ phase may be useful for identifying immunoactivation in previously immunotolerant carriers, which could be valuable for selecting patients for interferon therapy.
在慢性乙型肝炎病毒(HBV)感染中,X蛋白开放阅读框中核苷酸1762/1764处经常发生突变,核心启动子也位于此处。通过使用改良的等位基因特异性聚合酶链反应方法,研究了核苷酸1762处A→T突变的纵向出现与前核心突变、基因型和肝损伤的关系。首先,对38名携带者在乙肝e抗原(HBe)血清学转换前后采集的样本进行检测。在HBe血清学转换期间,T-1762突变株增加(P = 0.004)。在HBe抗原阴性(HBeAg-)阶段,在71%(17例中的12例)无伴随前核心突变(该突变可阻止HBeAg合成)的患者中发现了T-1762突变体,而在伴有前核心突变的患者中这一比例为33%(18例中的6例)(P = 0.08)。其次,在55例HBeAg阳性患者中,通过组织学活性指数(HAI)评分测量发现,T-1762突变体与更严重的肝脏炎症(P = 0.04)和纤维化(P = 0.02)相关。结果表明,核苷酸(nt)1762 A→T突变通常在HBe血清学转换期间发生,特别是在没有阻止HBeAg产生的前核心突变的毒株中。由于未知原因,T-1762突变体在B基因型毒株中很少见。HBeAg阳性阶段T-1762突变体的存在可能有助于识别先前免疫耐受携带者中的免疫激活情况,这对于选择干扰素治疗的患者可能具有重要价值。